| Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes M Kwon, SA Godinho, NS Chandhok, NJ Ganem, A Azioune, M Thery, ... Genes & development 22 (16), 2189-2203, 2008 | 735 | 2008 |
| A little CIN may cost a lot: revisiting aneuploidy and cancer NS Chandhok, D Pellman Current opinion in genetics & development 19 (1), 74-81, 2009 | 84 | 2009 |
| Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia EA Griffiths, HE Carraway, NS Chandhok, T Prebet Leukemia research 91, 106339, 2020 | 31 | 2020 |
| Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures B Diamond, B Ziccheddu, K Maclachlan, J Taylor, E Boyle, JA Ossa, ... Blood, The Journal of the American Society of Hematology 141 (19), 2359-2371, 2023 | 27 | 2023 |
| In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2 R Gbyli, Y Song, W Liu, Y Gao, G Biancon, NS Chandhok, X Wang, X Fu, ... Leukemia 36 (5), 1313-1323, 2022 | 15 | 2022 |
| Insights into novel emerging epigenetic drugs in myeloid malignancies NS Chandhok, T Prebet Therapeutic advances in hematology 10, 2040620719866081, 2019 | 11 | 2019 |
| Characteristics and clinical outcome of patients with clonal cytopenias of undetermined significance: a large retrospective multi-center international study Z Xie, MC Hyun, RS Komrokji, AM Zeidan, YF Madanat, JF Zeidner, ... Blood 138, 2158, 2021 | 7 | 2021 |
| Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape PC Boddu, AK Gupta, R Roy, BDLP Avalos, A Olazabal-Herrero, ... Molecular Cell 84 (8), 1475-1495. e18, 2024 | 6 | 2024 |
| The characteristics and prognosis of patients with clonal cytopenias of undetermined significance, including cancer and therapy-related clonal cytopenias Z Xie, A Smith, RS Komrokji, N Al Ali, AA Patel, C Saygin, AM Zeidan, ... Blood 140 (Supplement 1), 2887-2890, 2022 | 6 | 2022 |
| The PRIME Trial: PARP inhibition in IDH mutant effectiveness trial. A phase II study of olaparib in isocitrate dehydrogenase (IDH) mutant relapsed/refractory acute myeloid … NS Chandhok, W Wei, R Bindra, S Halene, Y Shyr, J Li, M Berens, ... Blood 134, 3909, 2019 | 6 | 2019 |
| A phase II clinical trial of E7820 for patients with Relapsed/Refractory myeloid malignancies with mutations in splicing factor genes JP Bewersdorf, MF Stahl, J Taylor, NS Chandhok, J Watts, A Derkach, ... Blood 140 (Supplement 1), 9065-9067, 2022 | 5 | 2022 |
| A phase 1a/b dose escalation study of the mutation agnostic FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia AD Goldberg, M Ohanian, P Koller, JK Altman, M Cherry, B Tomlinson, ... Blood 138, 1272, 2021 | 5 | 2021 |
| Hypomethylating agent based combinations in higher risk myelodysplastic syndrome NS Chandhok, R Lewis, T Prebet Leukemia & lymphoma 61 (5), 1012-1027, 2020 | 5 | 2020 |
| Real world outcomes of liposomal daunorubicin and cytarabine versus 7+ 3 in patients with secondary acute myeloid leukemia E Madarang, J Lykon, N Nguyen, JM Watts, TJ Bradley, NS Chandhok Blood 136, 5-6, 2020 | 4 | 2020 |
| Transcription elongation defects link oncogenic splicing factor mutations to targetable alterations in chromatin landscape PC Boddu, AK Gupta, R Roy, BDL Pena Avalos, AO Herrero, ... bioRxiv, 2023.02. 25.530019, 2023 | 3 | 2023 |
| Octogenarians with AML can have durable remissions with venetoclax and hypomethylating agent therapy despite significant dose reductions E Madarang, J Lykon, W Li, S Iyer, M Stanchina, N Nguyen, T Bradley, ... Blood 138, 1259, 2021 | 3 | 2021 |
| PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors R Gbyli, Y Song, W Liu, Y Gao, NS Chandhok, X Fu, X Wang, A Patel, ... Blood 134, 4222, 2019 | 3 | 2019 |
| What are the most promising new agents in myelodysplastic syndromes? NS Chandhok, PC Boddu, SD Gore, T Prebet Current opinion in hematology 26 (2), 77-87, 2019 | 3 | 2019 |
| E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial JP Bewersdorf, M Stahl, J Taylor, X Mi, NS Chandhok, J Watts, A Derkach, ... Leukemia 37 (12), 2512-2516, 2023 | 2 | 2023 |
| E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid Malignancies: A phase II clinical trial JP Bewersdorf, NS Chandhok, JM Watts, A Derkach, O Abdel-Wahab, ... Blood 142, 1547, 2023 | 2 | 2023 |
